Blog Archives

Our Patient is Cancer Free

3/31/2021

🔊 Our patient from Turkey entered our CERI Personalized Patient Program™ and we are so happy that after her 'delayed' treatment in Turkey due to Covid-19 in 2020, her recent biopsy via VATS (Video Assisted Thoracic Surgery) here in Boston confirmed TODAY that she's officially CANCER-FREE!! WOOHOO! 👍👏💪🎊🎉

Pictures to follow! Stay tuned 👉 @canceredinstitute

Show your love to her in the comments below and we'll be sure to show them to her. 🙏❤️👏💪👍

#Empowermentagainstcancer™
#CERICares
#BraveSouls

To learn more about our CERI Personalized Patient Program™ visit:
canceredinstitute.org/patient-program

100% of our completed cases, which includes patients with various cancer types, are to date still cancer-free! 👏💪

Please donate, so that we can save more lives! 🙏❤️

#lungcancer #nonsmallcelllungcancer #nsclc #lungcancerawareness #cancerfree #cancerpatient #cancersurvivor #cancertreatment #cancertreatmentworldwide #patientcare #patienteducation #patientguidance #wecanhelp #cancerpatientstories #cancerpatientprogram #yourenotalone #cancercareforall #cancertreatmentforall #qualityhealthcareforall #equalhealth #equalhealthcareforall

0 Comments

FDA approves lorlatinib for NSCLC

3/12/2021

0 Comments

The US Food and Drug Administration (FDA) has approved lorlatinib for metastatic ALK-positive NSCLC

On March 3, 2021, the Food and Drug Administration granted regular approval to lorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK-positive, detected by an FDA-approved test, Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.).
Lorlatinib received accelerated approval in November 2018 for the second- or third-line treatment of ALK-positive metastatic NSCLC.

This current approval is based on data from Study B7461006 (NCT03052608), a randomized, multicenter, open-label, active-controlled trial conducted in 296 patients with ALK-positive metastatic NSCLC who had not received prior systemic therapy for metastatic disease.

#Empowermentagainstcancer
#CERICares
#CERIinforms
#FDAapprovals

If you need help for your cancer treatment and care, apply to our CERI Personalized Patient Program™:
canceredinstitute.org/patient-program

Resources:
fda.gov/drugs/drug-approvals-and-databases/fda-approves-lorlatinib-metastatic-alk-positive-nsclc

#NSCLC #nonsmallcelllungcancer #AKLpositive #AKLpositiveNSCLC #lorlatinib #Lorbrena #pfizer #cancertreatment #ventana #ALKtest #fdaapproves #fdaapproved #cancertherapy

0 Comments

Happy International Womens Day

3/8/2021

0 Comments

Not just this day, but every day, we're celebrating powerful women around the globe and remind everyone that #equality is key for a healthy world. Happy International Women's Day!

#CERICares
#Empowermentagainstcancer™
#internationalwomensday
#womensday

We're powerful together!

#womensupportingwomen #mensupportingwomen #peoplesupportingpeople #kadınlargünümüzkutluolsun #kadinlargünü #weltfrauentag #eşitlik #gleichberechtigung #felizdiadelamujer #felizdiadamulher #giornatainternazionaledelladonna #смеждународнымженскимднем #uguaglianza #igualdade #igualdad

0 Comments

FDA approval for multiple myeloma treatment

3/2/2021

0 Comments

On February 26, 2021 the Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma.
Learn more about myeloma and multiple myeloma treatments on our website: canceredinstitute.org/myeloma-treatments

#Empowermentagainstcancer™
#CERIinforms
#CERICares
#CancerSimplified

Learn more about myeloma and multiple myeloma on our website: canceredinstitute.org/myeloma

If you need help for your cancer treatment and care, apply to our CERI Personalized Patient Program™: canceredinstitute.org/patient-program

#fdaapproval #FDA #multiplemyeloma #myeloma #multiplemyelomatreatment #multiplemyelomaawareness #myelomaawareness #MyelomaAwarenessMonth

0 Comments

Our Patient is Cancer Free

FDA approves lorlatinib for NSCLC

Happy International Womens Day

FDA approval for multiple myeloma treatment

Archives

Categories